CureVac says COVID vaccine produced immune response in early-stage trial
06 Jan 2023
VaccinemRNAClinical ResultClinical Study
Preview
Source: Reuters
Jan 6 (Reuters) - Germany's CureVac AG said on Friday its second-generation COVID-19 vaccineCOVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial.
The vaccine maker's U.S.-listed shares jumped 11% to $7.08 in premarket trading.
CureVac is developing the vaccine with Britain's GSK (GSK.L) and the companies are looking to catch-up to similar vaccine development by rivals.
The company said the vaccine was shown to be generally well tolerated in the trial. Younger adults showed the presence of neutralizing antibodies beginning at the lowest tested dose, data showed.
CureVac gave up on its first-generation vaccine candidate, CVnCoV, in 2021 after poor data.
"With this foundation, CureVac will turn the page and enter 2023 as a competitive player in the development of mRNA therapies," Chief Executive Franz-Werner Haas said.
The company also said its flu vaccine, which also uses mRNA technology, successfully boosted antibody levels against flu and was well-tolerated in an early-stage study.
Our Standards: The Thomson Reuters Trust Principles.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.